Loading video...
Video Failed to Load
We’ve published our first ever forward view, which provides a helpful overview of all the topics we are focusing on over the coming year. Explore our dedicated forward view webpage to find out more⬇️
24,950 views • 1 year ago •via X (Twitter)
10 Comments

Jonathan Benger, NICE CMO and deputy chief executive, talks about our new forward view, detailing how it will help stakeholders put guidance into practice. Find out more in his blog post:

Working with @sciencewise, we gathered public opinion on how NICE should prioritise its topics for guidance and advice to the health and care system. Read more:

NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation. Blog post🔽

Learn how our new approach to prioritisation is grounded in lived experience, in a blog post from @SDenegri OBE🔽

So disappointing @NICEComms is ignoring the needs of the 8 million people in the UK eczema community. There are no NICE quality guidelines for adolescents and adults with atopic eczema - just shocking.

A focus on neurology… does that mean that NICE Guidelines for #TouretteSyndrome will be considered a priority this time around? @TICYorkshire @tourettescot @tourettesaction

I may have missed this so do correct me. What about concerning topics on best practice for minoritised groups in all these areas. #InstituitionalRacism in medicine is continuing to deliver inequitable care & leading to unnecessary deaths in these populations.

I wish you would let me have Femara on prescription rather than the cheaper generics which give horrendous side effects. It's costing £90 per month. Prior to This I had foot scans, X-rays, consultations and GP appointments and all along it was with the coating or the filling 🤷♀️

It is disappointing to see there is still no focus on incorporating sustainability as part of much of this guidance. After our joint letter with many other healthcare orgs, would you commit to ensuring urgent change in this area?

Neurology? I've again been rejected as a candidate for Anti-CGRP meds for migraine. Breakthroughs in treatments are regularly announced in the media - but reality is most of us don't get a look-in when our lives COULD be transformed. Must be a matter of financial cost, as usual.



